Analyst firms · H.C. Wainwright · GMAB

H.C. Wainwright GMAB price target and rating history

Genmab A/S (GMAB) · Health Care

H.C. Wainwright rates Genmab A/S (GMAB) Buy with a $47 price target, as of its latest action on Jan 31, 2022. It has published 3 rating actions on GMAB since August 2021, including 1 upgrade and 2 downgrades. Across 6 firms with a GMAB price target in the last 12 months, the median target is $40.

Current rating
Buy
Price target
$47
Median target, all firms
$40
Actions on GMAB
3

H.C. Wainwright price target on GMAB

$52$47$4220222023202420252026
H.C. Wainwright price target on GMAB, each point a stated target, August 2021 to January 2022.

Every H.C. Wainwright rating on GMAB

How other firms rate GMAB

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
TD CowenBuy$43Jul 22, 2026
Truist SecuritiesBuy$40May 27, 2026
Goldman SachsBuyApr 22, 2026
Wolfe ResearchOutperform$32Mar 27, 2026
Wells FargoOverweight$40Mar 2, 2026
JefferiesBuy$41.50Feb 17, 2026
Morgan StanleyEqual-Weight$34Feb 17, 2026

Questions about H.C. Wainwright and GMAB

What is H.C. Wainwright's price target for GMAB?
H.C. Wainwright's latest stated price target for Genmab A/S (GMAB) is $47, from its action on Jan 31, 2022.
What is H.C. Wainwright's rating on GMAB?
H.C. Wainwright rates GMAB Buy, a bullish rating, as of Jan 31, 2022.
When did H.C. Wainwright last change its view on GMAB?
On Jan 31, 2022, H.C. Wainwright upgrades to Buy from Neutral, price target $47.
How does H.C. Wainwright's GMAB target compare with other analysts?
Across 6 firms with a GMAB price target in the last 12 months, the median target is $40.

More GMAB rating histories

All H.C. Wainwright ratingsGMAB news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.